Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Testosterone of less than 50 ng/dL~* Participants who was detected of disease progression on image or relapse of PSA (All PSA values measured 3 time at least one week interval are consecutively increased and final value is 2 ng/mL or more. If third value is not higher than second one, fourth measurement will be undertaken and its value must be higher than second one.)~* Participants who relapsed after CAB with bicalutamide~* Eastern Cooperative Oncology Group (ECOG) performance status is 0 or 1~* Aged 20 years or older~* Participants who provided written informed consent~Exclusion Criteria:~* Any prior treatment with enzalutamide, flutamide, abiraterone or chemotherapy, except for neoadjuvant therapy~* With active double cancer~* Any prior treatment with bicalutamide within 6 weeks~* Participants who received systemic biological therapy (except for existing approved drug for bone or treatment with luteinizing hormone-releasing hormone (LHRH) analogue) or received treatment with other antitumor agent for prostate cancer~* With serious complication~* History of hypersensitivity to enzalutamide or any other excipient of enzalutamide~* History of hypersensitivity to flutamide-containing agent~* With liver dysfunction~* Participants who are considered as inadequate by the investigator

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enzalutamide (Type: EXPERIMENTAL): Enzalutamide 160 mg administered orally once a day as four 40-mg soft capsules
- Flutamide (Type: ACTIVE_COMPARATOR): Flutamide 125 mg administered orally three times a day as one tablet after meal

Based on this trial design, predict the completion outcome and termination type (if applicable).